StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$17.73+1.03 (+6.17%)

Close on Nov 18, 2026Market cap $1.75BP/E –Yield –

Ultragenyx Pharmaceutical r&d expenses

Research and development expenses are spending on new products and technology.

Ultragenyx Pharmaceutical's R&D Expenses for the twelve months ending Jun 30, 2026 was $773.49M, up 12.3% year over year. For fiscal 2025 it was $750.00M, up 7.4% from the year before. Over ten years it grew 20.7% a year on average. The highest annual figure on record is $750.00M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$750.00M+7.4%
FY2024Dec 31, 2024$698.00M+7.7%
FY2023Dec 31, 2023$648.00M-8.2%
FY2022Dec 31, 2022$705.79M+42.0%
FY2021Dec 31, 2021$497.15M+20.6%
FY2020Dec 31, 2020$412.08M+15.3%
FY2019Dec 31, 2019$357.36M+21.6%
FY2018Dec 31, 2018$294.00M+26.9%
FY2017Dec 31, 2017$231.64M+26.4%
FY2016Dec 31, 2016$183.20M+59.7%
FY2015Dec 31, 2015$114.74M+149.6%
FY2014Dec 31, 2014$45.97M+65.2%
FY2013Dec 31, 2013$27.83M+120.1%
FY2012Dec 31, 2012$12.64M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$167.00M+1.2%
Q1 FY2026Mar 31, 2026$187.00M+12.7%
Q4 FY2025Dec 31, 2025$203.28M+8.2%
Q3 FY2025Sep 30, 2025$216.21M+27.1%
Q2 FY2025Jun 30, 2025$165.00M+2.2%
Q1 FY2025Mar 31, 2025$166.00M-7.0%
Q4 FY2024Dec 31, 2024$187.90M+17.4%
Q3 FY2024Sep 30, 2024$170.11M+8.2%
Q2 FY2024Jun 30, 2024$161.50M-2.1%
Q1 FY2024Mar 31, 2024$178.49M+7.7%
Q4 FY2023Dec 31, 2023$160.11M-6.3%
Q3 FY2023Sep 30, 2023$157.25M-33.7%
Q2 FY2023Jun 30, 2023$164.95M+6.7%
Q1 FY2023Mar 31, 2023$165.70M+15.7%
Q4 FY2022Dec 31, 2022$170.81M+38.9%
Q3 FY2022Sep 30, 2022$237.30M+109.2%
Q2 FY2022Jun 30, 2022$154.53M+36.5%
Q1 FY2022Mar 31, 2022$143.16M-3.0%
Q4 FY2021Dec 31, 2021$123.01M-6.2%
Q3 FY2021Sep 30, 2021$113.42M+29.9%
Q2 FY2021Jun 30, 2021$113.21M+40.3%
Q1 FY2021Mar 31, 2021$147.52M+30.6%
Q4 FY2020Dec 31, 2020$131.10M+57.8%
Q3 FY2020Sep 30, 2020$87.31M-12.8%
Q2 FY2020Jun 30, 2020$80.71M-16.0%
Q1 FY2020Mar 31, 2020$112.96M+44.6%
Q4 FY2019Dec 31, 2019$83.06M+16.0%
Q3 FY2019Sep 30, 2019$100.14M+43.0%
Q2 FY2019Jun 30, 2019$96.05M+25.0%
Q1 FY2019Mar 31, 2019$78.11M+3.4%
Q4 FY2018Dec 31, 2018$71.62M+16.4%
Q3 FY2018Sep 30, 2018$70.04M+15.9%
Q2 FY2018Jun 30, 2018$76.84M+31.5%
Q1 FY2018Mar 31, 2018$75.50M+47.3%
Q4 FY2017Dec 31, 2017$61.53M+21.2%
Q3 FY2017Sep 30, 2017$60.41M+24.0%
Q2 FY2017Jun 30, 2017$58.44M–
Q1 FY2017Mar 31, 2017$51.27M–
Q4 FY2016Dec 31, 2016$50.75M–
Q3 FY2016Sep 30, 2016$48.71M–

More Ultragenyx Pharmaceutical figures

See a number that looks wrong?